What is Palatin?
Palatin Technologies, Inc. is a biopharmaceutical firm dedicated to the development of targeted, receptor-specific peptide therapeutics aimed at treating a spectrum of diseases. The company's lead candidate, Bremelanotide, is an injectable peptide melanocortin receptor agonist currently in Phase III clinical trials for hypoactive sexual desire disorder (HSDD) in premenopausal women. Palatin's research extends to other therapeutic areas, including preclinical studies for conditions like erectile dysfunction, obesity, and diabetes, as well as inflammatory and dermatologic diseases. Furthermore, the company is advancing natriuretic peptide receptor-specific programs, with PL-3994 in Phase II trials for heart failure and related conditions. Founded in 1986, Palatin's strategic focus on novel peptide therapeutics positions it within a critical segment of the pharmaceutical industry.
How much funding has Palatin raised?
Palatin has raised a total of $93.8M across 9 funding rounds:
Other Financing Round
$1.8M
Multiple Rounds
$31.9M
Debt
$10M
Share Placement
$19.8M
Share Placement
$9.2M
Share Placement
$16.5M
Other Financing Round
$4.7M
Other Financing Round (2013): $1.8M with participation from Commercialization Center for Innovative Technologies
Other Financing Round (2014): $1.9M led by Commercialization Center for Innovative Technologies
Share Placement (2014): $20M supported by QVT Financial
Debt (2014): $10M featuring Horizon Technology Finance Corporation
Debt (2015): $10M backed by Horizon Technology Finance Corporation
Share Placement (2015): $19.8M with participation from QVT Financial
Share Placement (2016): $9.2M, investors not publicly disclosed
Share Placement (2016): $16.5M, investors not publicly disclosed
Other Financing Round (2023): $4.7M featuring Commercialization Center for Innovative Technologies
Key Investors in Palatin
QVT Financial
QVT Financial is an investment firm known for its diverse group of original thinkers and unique expertise in smart investment strategies. The firm focuses on various core areas including biotech, technology, energy, and financials, offering innovative and diverse investment solutions.
Horizon Technology Finance Corporation
Horizon Technology Finance Corporation is a specialty finance company providing structured debt financing solutions to development-stage companies, primarily in technology and life sciences. They offer venture lending to businesses backed by venture capital and private equity investors.
Commercialization Center for Innovative Technologies
The Commercialization Center for Innovative Technologies, associated with the New Jersey Economic Development Authority, focuses on driving economic growth and supporting innovative companies within the state through strategic initiatives and funding.
What's next for Palatin?
The substantial enterprise-level backing Palatin Technologies has received, particularly the recent strategic investment, signals a pivotal phase for the company. This capital infusion is expected to accelerate the clinical development of its key drug candidates, including Bremelanotide and PL-3994, through their respective late-stage trials. The company's strategic financing will likely support expanded research into its broader pipeline of melanocortin receptor agonists and natriuretic peptide receptor programs. Palatin's trajectory suggests a continued focus on advancing its therapeutic innovations towards commercialization, aiming to address unmet medical needs in sexual health, cardiovascular diseases, and metabolic disorders.
See full Palatin company page
